BR112017001017A2 - composições em suspensão de ciclosporina a para injeção subconjuntival e periocular - Google Patents

composições em suspensão de ciclosporina a para injeção subconjuntival e periocular

Info

Publication number
BR112017001017A2
BR112017001017A2 BR112017001017A BR112017001017A BR112017001017A2 BR 112017001017 A2 BR112017001017 A2 BR 112017001017A2 BR 112017001017 A BR112017001017 A BR 112017001017A BR 112017001017 A BR112017001017 A BR 112017001017A BR 112017001017 A2 BR112017001017 A2 BR 112017001017A2
Authority
BR
Brazil
Prior art keywords
cyclosporine
suspension
subconjunctival
suspension compositions
periocular injection
Prior art date
Application number
BR112017001017A
Other languages
English (en)
Inventor
V Gore Anuradha
P Pujara Chetan
Hou Hao
Wu Ke
Neervannan Sesha
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762390&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017001017(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112017001017A2 publication Critical patent/BR112017001017A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente divulgação refere-se a formulações em suspensão e a sistemas para o tratamento de condições oculares. as formulações em suspensão podem incluir ciclosporina a e, em algumas modalidades, a ciclosporina a da forma 1 ou de forma 2. pode ser fornecido um sistema de distribuição que inclui duas partes, uma primeira parte que contém partículas de ciclosporina, e uma segunda parte que contém outros componentes que podem ser combinados com a primeira parte para produzir uma formulação em suspensão. a suspensão pode ser injetada no espaço subconjuntival ou em outro espaço periocular para tratar condições oculares, tais como a doença do olho seco.
BR112017001017A 2014-07-18 2015-07-20 composições em suspensão de ciclosporina a para injeção subconjuntival e periocular BR112017001017A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462026200P 2014-07-18 2014-07-18
PCT/US2015/041166 WO2016011449A1 (en) 2014-07-18 2015-07-20 Suspension compositions of cyclosporin a for subconjunctival and periocular injection

Publications (1)

Publication Number Publication Date
BR112017001017A2 true BR112017001017A2 (pt) 2018-01-23

Family

ID=53762390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001017A BR112017001017A2 (pt) 2014-07-18 2015-07-20 composições em suspensão de ciclosporina a para injeção subconjuntival e periocular

Country Status (14)

Country Link
US (1) US10780048B2 (pt)
EP (1) EP3169308B1 (pt)
KR (1) KR20170030093A (pt)
AU (1) AU2015289387B2 (pt)
BR (1) BR112017001017A2 (pt)
CA (1) CA2955037A1 (pt)
CL (1) CL2017000120A1 (pt)
CO (1) CO2017001454A2 (pt)
MX (1) MX2017000855A (pt)
MY (1) MY196111A (pt)
PH (1) PH12017500098A1 (pt)
RU (1) RU2713953C2 (pt)
SA (1) SA517380738B1 (pt)
WO (1) WO2016011449A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587412B1 (ko) * 2014-10-17 2016-01-21 주식회사 휴온스 사이클로스포린 및 트레할로스를 포함하는 안과용 조성물
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
US20180098937A1 (en) * 2016-10-12 2018-04-12 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
CN112315901B (zh) * 2019-07-17 2022-10-25 四川弘合生物科技有限公司 一种注射用浓溶液及其制备方法
US11298315B2 (en) 2020-08-26 2022-04-12 Somerset Therapeutics, Llc. Triamcinolone and moxifloxacin compositions
US11484538B2 (en) 2020-08-26 2022-11-01 Somerset Therapeutics, Llc Bromfenac, prednisolone, and moxifloxacin compositions and methods
US11382910B2 (en) 2020-08-26 2022-07-12 Somerset Therapeutics, Llc. Loteprednol and moxifloxacin compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252319A (en) 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP1142566B1 (fr) * 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
KR20100102749A (ko) 2002-02-22 2010-09-24 산텐 세이야꾸 가부시키가이샤 미립자 결막하 투여를 위한 약물 수송 시스템
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8288348B2 (en) * 2005-07-13 2012-10-16 Allergan, Inc. Cyclosporin compositions
MX2008012794A (es) * 2006-04-03 2008-10-15 Teva Pharma Microparticulas de farmacos.
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
US20090081277A1 (en) 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
UA113627C2 (xx) 2011-05-27 2017-02-27 Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
ES2666191T3 (es) 2011-11-15 2018-05-03 Allergan, Inc. Un proceso para la cristalización de la forma 2 de la ciclosporina A
WO2013074616A1 (en) 2011-11-15 2013-05-23 Allergan, Inc. Autoclavable suspensions of cyclosporin a form 2
US8785394B2 (en) 2011-11-15 2014-07-22 Allergan, Inc. Sustained action formulation of cyclosporin form 2
ES2791751T3 (es) 2011-11-15 2020-11-05 Allergan Inc Suspensiones de forma 2 de ciclosporina A

Also Published As

Publication number Publication date
MX2017000855A (es) 2017-05-01
CL2017000120A1 (es) 2017-09-08
MY196111A (en) 2023-03-15
EP3169308B1 (en) 2021-01-27
WO2016011449A1 (en) 2016-01-21
KR20170030093A (ko) 2017-03-16
US20160015632A1 (en) 2016-01-21
RU2017103632A (ru) 2018-08-20
EP3169308A1 (en) 2017-05-24
RU2713953C2 (ru) 2020-02-11
PH12017500098A1 (en) 2017-05-22
CO2017001454A2 (es) 2017-02-28
RU2017103632A3 (pt) 2019-02-01
CA2955037A1 (en) 2016-01-21
AU2015289387B2 (en) 2020-10-22
SA517380738B1 (ar) 2021-04-11
AU2015289387A1 (en) 2017-02-23
US10780048B2 (en) 2020-09-22

Similar Documents

Publication Publication Date Title
BR112017001017A2 (pt) composições em suspensão de ciclosporina a para injeção subconjuntival e periocular
BR112015028605A8 (pt) uso de uma composição e uso de um imunossupressor e uma composição
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
SV2018005787A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
CL2020002019A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
NZ730865A (en) Peptides having anti-inflammatory properties
BR112015027288A2 (pt) nanocarreadores sintéticos tolerogênicos e macromoléculas terapêuticas para efeitos farmacodinâmicos acentuados ou reduzidos
CL2018000899A1 (es) Compuestos y métodos para modular expresión de angiotensinógeno.
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
MX2017012426A (es) Composiciones y metodos para modular la expresion de tmprss6.
BR112015032341A2 (pt) conservação de composições para cuidados pessoais
BR112017007813A2 (pt) composições oftalmológicas, método de prevenção, redução ou tratamento de transtornos causados por olhos secos e uso de ciclosporina e trealose
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112018013063A2 (pt) combinação terapêutica inibidora de bromodomínio e proteína extra-terminal
BR112015015870A2 (pt) composição farmacêutica
CL2019001092A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
BR112016025659A8 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
BR112018071684A2 (pt) composições e métodos para o tratamento de doenças ou distúrbios de armazenamento lisossômico que tem como característica disfunção lisossomal
BR112015015864A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
BR112018010945A2 (pt) formulações com degradação de polissorbato reduzida
BR112016017509A2 (pt) composições e métodos compreendendo uma variante da enzima xilanase
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
BR112018072452A2 (pt) nanopartículas de glicogênio e fitoglicogênio como compostos imunossupressores, e composições e métodos para uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]